# US 2020/0399345 A1 · Methods of use of soluble cd24 for therapy of rheumatoid arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399345 A1
- Document ID: US20200399345A1
- Status: Published application
- Kind: A1
- Application number: 17/009,540
- Filed: 2020-09-01
- Published: 2020-12-24
- Earliest claimed: 2010-04-28
- Assignees: Oncoimmune, Inc.
- Applicants: OncoImmune, Inc.
- Inventors: Xincheng Zheng; Wei Wu; Yang Liu; Pan Zheng
- Web page: https://patentgrep.com/patent/US20200399345A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

## Claims

### Claim 1

A CD24 protein comprising a mature human CD24 variant consisting of SEQ II) NO: 1.

### Claim 2 (depends on 1)

The CD24 protein of claim 1, wherein the CD24 protein is soluble.

### Claim 3 (depends on 1)

The CD24 protein of claim 1, wherein the CD24 protein is glycosylated.

### Claim 4 (depends on 1)

The CD24 protein claim 1, wherein the CD24 protein further comprises a portion of a mammalian immunoglobulin (Ig), which is fused to the N-terminus or C-terminus of the mature CD24.

### Claim 5 (depends on 4)

The CD24 protein of claim 4, wherein the Ig portion is the Fe portion of a human Ig protein.

### Claim 6 (depends on 5)

The CD24 protein of claim 5, wherein the portion consists of the hinge region and CH2 and CH3 domains of the human Ig protein, and wherein the Ig is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and IgA.

### Claim 7 (depends on 5)

The CD24 protein of claim 5, wherein the Fe portion consists of the hinge region and CH3 and CH4 domains of IgM.

### Claim 8 (depends on 1)

The CD24 protein of claim 1, wherein the CD24 protein is produced using a eukaryotic protein expression system.

### Claim 9 (depends on 8)

The CD24 protein of claim 8, wherein the expression system comprises a vector contained in a Chinese Hamster Ovary cell line or a replication-defective retroviral vector.

### Claim 10 (depends on 9)

The CD24 protein of claim 9, wherein the replication-defective retroviral vector is stably integrated into the genome of a eukaryotic cell.